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Abstract
Background:  With the control of many infections through national vaccination programmes, varicella is
currently the most widespread preventable childhood disease in industrialized nations. In 2005 varicella
vaccination was added to the Veneto Region routine immunization schedule for all children at 14 months of age
and 12 year-old susceptible adolescents through an active and a free of charge offer. To evaluate parameters at
the start of the programme, we conducted a study to describe the epidemiology of varicella infection and
coverage rates for varicella vaccine in the Veneto Region (North-East Italy).
Methods: We examined incidence rates and median age of case patients in the Veneto Region for 2000-2007
period using two data sources: the mandatory notification of infections diseases and the Italian Paediatric Sentinel
Surveillance System of Vaccine Preventable Diseases. Corrected coverage rates were calculated from data
supplied by the Public Health and Screening Section of the Regional Department for Prevention.
Results: In the Veneto Region from 2000 to 2007, a total of 99,351 varicella cases were reported through
mandatory notifications, mostly in children under 15 years of age. The overall standardised annual incidence
ranged from 2.0 to 3.3 per 1,000 population, with fluctuations from year to year. The analysis by geographic area
showed a similar monthly incidence rate in Italy and in the Veneto Region. The vaccination average adherence
rate was 8.2% in 2004 cohort, 63.5% in 2005 cohort and 86.5% in 2006 cohort. Corrected coverage rates were
8.1% in 2004 cohort, 59.9% in 2005 cohort and 70.0% in 2006 cohort, respectively.
Conclusion: Data from passive and active surveillance systems confirm that varicella is a common disease which
each year affects a large proportion of the population, mainly children. Uptake of the varicella vaccination
programme was strikingly good with average coverage rates of about 70% after only 3 years. Sustained
implementation of existing vaccine policies is needed to warrant any significant reduction of varicella incidence in
the Veneto Region. Continued surveillance will be important to monitor the impact of the recently introduced
mass vaccination policy.
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Background
Varicella-zoster virus is the causal agent of varicella (chick-
enpox) currently the most widespread preventable child-
hood disease in industrialised nations where many other
infections are well-controlled by national vaccination
programmes [1,2]. Primary varicella infection is a highly
contagious illness characterised by a maculo-papulo-
vesicular rash associated with fever and malaise [3]. It is
usually considered a mild self-limiting disease. Neverthe-
less, serious complications such as bacterial super-infec-
tion, pneumonia, central nervous system diseases can
occur and may lead to hospitalisation and even death
[2,4]. Infants, adolescents and immunocompromised
people are at higher risk [5].
In a non-vaccinated population the risk of acquiring vari-
cella is over 95% and most people contract this infection
before the age of 20 [2]. The disease is endemic in most
populations worldwide. According to the Centres for Dis-
ease Control and Prevention (CDC), the incidence of vari-
cella is assumed to approximate the annual birth cohort
[6].
In the absence of universal childhood vaccination pro-
gramme, varicella incidence peaks in children under 10
years of age, with the highest incidence rates between 3
and 6 years of age [7].
Prevention of infection by vaccination is the optimal
approach in the management of varicella. World Health
Organization recommends routine childhood immuniza-
tion to be considered in countries where the disease is a
relatively important public health and socio-economic
problem and where high and sustained vaccination cover-
age rates can be achieved [8]. Indeed, in case of subopti-
mal coverage rates, the positive effects of vaccinating
children might be offset by a shift of infection to older
age-groups who are at risk of more severe disease [2,9].
After the licensure of varicella vaccine in the United States
(US) in 1995, the Advisory Committee on Immunisation
Practices (ACIP) recommended routine vaccination with
one dose of varicella vaccine for all children 12-18
months of age and catch up of all susceptible children 19
months to 12 years of age; vaccination with 2 doses was
recommended for all susceptible people ≥ 13 years of age
[5]. The implementation of these recommendations was
followed by a marked decline in the incidence of varicella,
its complications and related mortality [1,10-12]. How-
ever, while varicella incidence reached its lowest level, fur-
ther decrease was not observed and outbreaks in school
populations with high coverage rates for varicella vaccina-
tion were reported [13-17]. To further reduce varicella
incidence and its complications and to control outbreaks,
ACIP issued new recommendations on the use of varicella
vaccine including a second dose routinely administered at
4 to 6 years of age in those subjects previously vaccinated
with 1 dose [5].
In January 2005, varicella vaccine was introduced in the
Veneto Region (North-East Italy) vaccination schedule
(Regional Law No. 4403 of 30 December 2005). The
active and free of charge offer concerned children aged 14
months and 12 years-old adolescents with a negative his-
tory for varicella. Following ACIP recent discussion on
varicella vaccination, the Veneto Region expanded its rec-
ommendation to a second dose of varicella vaccine for 6
year-old children as part of routine childhood immunisa-
tion and a catch up dose for teenagers was confirmed. In
this paper we discuss the epidemiological trends of vari-
cella infections as well as varicella vaccination coverage
rates in the Veneto Region.
Methods
Epidemiological data included all new cases of varicella
reported, in the period 2000-2007, to the Regional
Department for Prevention, Public Health and Screening
Section, in accordance with the Italian Communicable
Disease Act. For each subject affected by chickenpox,
available data include specific information on the date of
diagnosis, varicella vaccine status and demographic data.
To conduct a more in-depth epidemiological evaluation,
we also analysed incidence data from a nationwide senti-
nel system, the Italian Paediatric Sentinel Surveillance Sys-
tem of Vaccine Preventable Disease (SPES). Data are
available from the official web-site coordinated by the
National Institute of Health [18].
Furthermore, with the launch of varicella vaccination pro-
gramme on 1st January 2005, we studied vaccination cov-
erage rates observed in 14 months-old children. A
retrospective analysis was conducted from 1st  January
2005 to 31st December 2007 considering all infants born
between 2004-2006 in the Veneto Region.
At the start of the vaccination programme, only monova-
lent varicella vaccine were distributed in Italy, Varivax®
(manufactured by Merck and distributed in Europe by
Sanofi Pasteur MSD) and Varilrix® (Glaxo Smith Kline). In
the spring of 2007, a quadrivalent combination measles,
mumps, rubella, and varicella (MMRV) vaccine (Pro-
Quad® manufactured by Merck and distributed in Europe
by Sanofi Pasteur MSD) was made available as an alterna-
tive for concomitant vaccination against the 4 diseases.
Data was supplied by the Public Health and Screening
Section of the Regional Department for Prevention. Public
Health Services that includes information obtained from
all of the 21 Veneto Health Care Units. Data included the
number of eligible children in the investigated periodBMC Infectious Diseases 2009, 9:150 http://www.biomedcentral.com/1471-2334/9/150
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(resident population of children born between 1/1/2004
and 12/31/2006) and the number of 14 months-old chil-
dren vaccinated against measles, mumps, rubella and vari-
cella.
Annual and age specific incidence rates were calculated
per 1,000 population, using the latest census data for year
2001 (National Institute of Statistics) and data provided
by the Veneto Region Statistical Bureau for the remaining
years.
Children with a reliable history of varicella as well as
those previously vaccinated were deemed to be protected
[6]. Corrected coverage rate for varicella was calculated to
estimate the proportion of children protected against vari-
cella: both children who received the first dose of MMRV
quadrivalent combination or monovalent varicella vac-
cine as well as those with a positive history of varicella
infection were considered for this calculation.
Furthermore, adherence rates were calculated on the pop-
ulation responding to the active offer (solicited children)
taking into account the total number of vaccinated chil-
dren (with MMRV or varicella vaccine). The population of
solicited children comprised all the children who received
measles vaccine (all formulation types) and excluded sub-
jects with a history of varicella infection.
Results
In the Veneto Region, from 2000 to 2007, a total of
99,351 varicella cases were reported through mandatory
notifications of infections diseases. During this period,
the overall standardised annual incidence ranged from 2.0
to 3.3 per 1,000 population, with fluctuations from year
to year. Most of the cases were reported during the spring
months with an incidence rate peaking in children aged 1
to 4 years (31.3 cases per 1,000 population). Ninety one
percent of cases occurred among children under 15.
Adults had the lowest rate of reported cases and accounted
for 8.0% (0.3 per 1,000 population), as shown in Table 1.
SPES data on varicella showed incidence rates per 1,000
population in children less than 14 years of 53.4 in 2000,
57.4 in 2001, 54.6 in 2003, 66.6 in 2004, 40.5 in 2005,
60.6 in 2006 and 46.3 in 2007, respectively (Figure 1).
Similar monthly incidence rates were reported for Italy
and the Veneto Region, with a mean ratio of 0.9 (range 0.3
to 3.2). Data obtained from the different surveillance sys-
tems for the Veneto Region showed monthly varicella
incidence in 0-14 years-old children ranging from 0.1 to
15.3 per 1,000 population as reported by SPES, while data
obtained through mandatory notifications ranged from
0.0 to 4.3 per 1,000 population. Overall, sentinel network
incidence data was 4.2 time higher than that reported by
statutory notification (range 1.1-11.9).
A summary of vaccinated children in the target popula-
tion by cohort of birth is given in Table 2. The average
adherence rate was 8.2% in 2004 cohort, 63.5% in 2005
cohort and 86.5% in 2006 cohort. Corrected coverage
rates were 8.1% (range 2.6 - 18.5%) in 2004 cohort,
59.9% (range 27.7 - 79.9%) in 2005 cohort and 70.0%
(range 51.5- 85.2%) in 2006 cohort. MMRV and monova-
lent varicella vaccine were administered to 2005 cohort in
2.9% (1,312) and 55.1% (25,320) children repectively,
while the same vaccines were almost equally gave to 2006
cohort.
Discussion and conclusion
In the Veneto Region the epidemiology of varicella shows
a seasonal pattern with a peak incidence during the spring
months (March thought May), and a lower incidence in
late summer and early autumn. Few studies in the litera-
ture analysed seasonal trends of varicella infections.
Indeed, most papers focus on the complications related to
varicella such as hospitalisations and deaths [5,11,19].
Our data confirm the burden of varicella, a common dis-
ease which affects a large proportion of the population
each year, as demonstrated by the high overall standard-
ised annual incidence rate. As expected, the infection is
predominantly a paediatric disease with only 9.6% of
cases in subjects ≥ 15 years; these results are in line with
Table 1: Reported cases of varicella cases and rates per 1,000 population among the Veneto Region residents by age group and year.
Year Age group
<1 1-4 5-9 10-14 15-19 ≥ 20 Total
2000 207 (4,8) 5256 (30,6) 5215 (25,5) 949 (4,6) 316 (1,6) 1182 (0,3) 13188 (2,9)
2001 179 (4,3) 5094 (30,1) 4561 (22,6) 693 (3,5) 201 (1,0) 1047 (0,3) 11871 (2,6)
2002 209 (4,8) 5139 (30,0) 4775 (23,4) 674 (3,3) 202 (1,0) 952 (0,3) 11985 (2,6)
2003 243 (5,5) 6085 (34,8) 5302 (25,4) 730 (3,5) 203 (1,0) 1133 (0,3) 13753 (3,0)
2004 291 (6,3) 6926 (39,0) 5871 (27,4) 762 (3,6) 208 (1,0) 1225 (0,3) 15283 (3,3)
2005 217 (4,7) 4611 (25,5) 3505 (15,9) 377 (1,8) 150 (0,7) 944 (0,2) 9819 (2,1)
2006 279 (6,0) 6685 (36,4) 4982 (22,3) 615 (2,9) 163 (0,8) 895 (0,2) 13644 (2,9)
2007 181 (3,8) 4511 (24,1) 3956 (17,4) 428 (2,0) 98 (0,4) 632 (0,2) 9808 (2,0)BMC Infectious Diseases 2009, 9:150 http://www.biomedcentral.com/1471-2334/9/150
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recent Italian seroprevalence data [20]. Although it is too
early to observe an effect of the new vaccination schedule,
such baseline data are precious for further evaluation of
the programme, in particular with regard to its impact on
the incidence of varicella and its complications over time
and possible herd immunity effects. In the US, active sur-
veillance conducted in three different areas showed a dra-
matic decrease in disease incidence, correlated
hospitalizations and mortality after only 5 years of univer-
sal vaccination programme. With vaccination coverage
rates in 19-35 months-old children ranging from 74-84%,
varicella cases were reduced by 71-84% [1] while corre-
sponding data after 11 years of varicella vaccination, were
92-93% for coverage rates and ~90% for varicella inci-
dence decline as observed in two different surveillance
areas (89.9% and 90.4%) [21].
In our paper we examined data from the national routine
notification system. This is a passive surveillance system
which is useful to analyse trends of varicella but inaccu-
rate to measure disease incidence due to under notifica-
tion and under diagnosis [22]. Indeed, data observed by
SPES, a voluntary paediatric sentinel surveillance system,
were 1.1 to 11.9 times higher than those obtained
through mandatory notifications, clearly showing a sub-
stantially higher sensitivity of SPES sentinel surveillance
system when compared to compulsory notifications, as
already shown in previous studies [20,23].
Monthly incidence rate in children 0-14 years old per 1,000 population reported by SPES and mandatory notifications (2000- 2007) Figure 1
Monthly incidence rate in children 0-14 years old per 1,000 population reported by SPES and mandatory noti-
fications (2000-2007).
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Table 2: Number of vaccinated children and coverage rate by birth cohort.
Birth cohort
2004 2005 2006
Resident children 45934 45918 45047
Susceptible children 45303 45064 44407
Solicited children 37717 41935 35477
Adherence rate (%) 8.2 63.5 86.5
Vaccinated children 3103 26632 30692
measles, mumps, rubella, and varicella vaccine 44 1312 15606
monovalent varicella vaccine 3059 25320 15086
Coverage rate [range] (%) 6.8 [0.9-18.3] 58.0 [24.6-79.1] 68.1 [48.6-82.7]
Corrected coverage rate [range] (%) 8.1 [2.6-18.5] 59.9 [27.7-79.9] 69.7 [51.5-85.2]BMC Infectious Diseases 2009, 9:150 http://www.biomedcentral.com/1471-2334/9/150
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Overall, varicella has a significant impact that can be
addressed by universal vaccination much better than
symptomatic and antiviral treatments [3]. Prevention has
a number of overall health care advantages, in particular
with regard to reduction of complications and health care
costs as well as improvement in quality of life [11,12,24].
In this scenario the Veneto Region in 2005 introduced an
universal vaccination program for varicella, aiming at
achieving high vaccination coverage in the target popula-
tion in order to prevent the accumulation of a susceptible
population at risk of more severe disease. Hence it is fun-
damental to reach high coverage rates in the shortest time
[25]. The rapid uptake of varicella vaccination in the
Veneto Region is striking, reaching in just three years a
corrected coverage rate of 69.7%, very close to target vac-
cination coverage of 80% for children 14 month-old. Of
note, to calculate corrected coverage rates we estimated
the proportion of varicella history positive subjects using
mandatory notifications. While these latter represented
2% in our study, it is interesting to mention that another
recent study conducted in the same area reported 7% sub-
jects with varicella history [26]. Overall, our study might
have underestimated the true corrected coverage rates.
According to a model developed by the Italian National
Institute of Health and Tor Vergata University (Rome), a
vaccination coverage of 80% for newborns (14 months)
and 50% in susceptible adolescents (12 years-old) would
result in a 94% drop in varicella cases [27]. Continued
monitoring will be needed to understand the impact of
vaccination on the epidemiology of this disease and its
complications, including herpes zoster [3,28,29].
Similar to ACIP recommendations in 2007 [5], our pro-
gramme introduced the use of a combined multivalent
MMRV vaccine as an alternative to measles, mumps,
rubella and varicella monovalent vaccine in separate
injections, offering the convenience of a single injection
to facilitate the introduction of varicella vaccination
within the routine childhood immunisation schedule
[30]. However, US surveillance systems detected a signal
of increased incidence of febrile seizures in subjects vacci-
nated with MMRV when compared to separate vaccines,
particularly after the first dose. Consequently, MMRV was
withdrawn by ACIP in February 2008 without any change
in overall recommendations for varicella vaccination. A
workgroup was also nominated to continue the monitor-
ing of MMRV safety and provide relevant data for future
policy options [31]. In Veneto, the choice of MMRV over
separate injections is left to the physician and subject deci-
sion while monitoring of safety is already in place through
a very efficient pharmacovigilance system which repre-
sents an invaluable tool to assess vaccine safety in the long
term.
Universal vaccination can dramatically reduce the inci-
dence of varicella, varicella associated complications, hos-
pitalisation rates and fatality and this has been
demonstrated through the large US experience [21]. Sus-
tained implementation of existing vaccine policies is
needed to warrant any significant reduction of varicella
incidence in the Veneto Region. Additionally, a parallel
surveillance of the disease in the population and coverage
rates among adolescence as well as young children will be
fundamental to evaluate the impact of the vaccination
strategy and policy.
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